8-K
filed May 2, 2022, 7:59 PM ET
ticker WGS
CIK 0001818331
M&A
confidence high
sentiment positive
materiality 0.80
Sema4 closes GeneDx acquisition; Stueland becomes CEO, Schadt shifts to President
GeneDx Holdings Corp.
- Acquired GeneDx for $150M cash + 80M shares upfront; up to $150M in revenue-based milestones.
- Closed $200M PIPE at $4.00/share with institutional investors including Pfizer.
- Katherine Stueland appointed CEO; Eric Schadt becomes President & Chief R&D Officer.
- Board expanded to 11; Stueland and Richard Pfenniger elected as Class III directors.
- Authorized Class A common shares increased from 380M to 1B via charter amendment.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Eric Schadt was appointed as President and Chief Research & Development Officer at GeneDx Holdings Corp..
- Action
- appointed
- Role
- President and Chief Research & Development Officer
Exact text from the filing
In connection with the Closing, Eric Schadt was appointed President and Chief Research & Development Officer of the Company and ceased serving as the Chief Executive Officer effective as of April 29, 2022.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Katherine Stueland was elected as Class III Director at GeneDx Holdings Corp..
- Action
- elected
- Role
- Class III Director
Exact text from the filing
Katherine Stueland and Richard P. Pfenniger were each elected to the Board of Directors as Class III directors effective as of April 29, 2022
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Richard P. Pfenniger was elected as Class III Director at GeneDx Holdings Corp..
- Action
- elected
- Role
- Class III Director
Exact text from the filing
Katherine Stueland and Richard P. Pfenniger were each elected to the Board of Directors as Class III directors effective as of April 29, 2022
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Katherine Stueland was appointed as Co-Chief Executive Officer at GeneDx Holdings Corp..
- Action
- appointed
- Role
- Co-Chief Executive Officer
Exact text from the filing
Katherine Stueland was appointed as Co-Chief Executive Officer of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Nat Turner resigned as Director at GeneDx Holdings Corp..
- Action
- resigned
- Role
- Director
Exact text from the filing
Effective as of April 29, 2022, Nat Turner resigned from his position on the Board of Directors of the Company and all committees thereof
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.